Long-term prognostic value of right ventricular dysfunction on cardiovascular magnetic resonance imaging in anthracycline-treated cancer survivors
Authors:
- 23 July 2021
- journal article
- research article
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Imaging
- Vol. 23 (9) , 1222-1230
Abstract
We aimed to determine the prevalence of right ventricular (RV) systolic dysfunction on cardiovascular magnetic resonance imaging (CMR) and its impact on long-term adverse outcomes in a large cohort of cancer survivors treated with anthracycline-based chemotherapy. Consecutive cancer survivors treated with anthracyclines who underwent clinical CMR for suspected anthracycline-related cardiomyopathy were studied. The primary endpoint was a composite of all-cause death or major adverse cardiac events (MACE): heart failure hospitalization, heart transplantation, ventricular assist device implantation, resuscitated cardiac arrest, or life-threatening ventricular arrhythmia. The secondary endpoints were all-cause death, and cardiac death or MACE. Among 249 survivors who underwent CMR at a median of 2.9 years after cancer treatment, RV systolic dysfunction was present in 54 (21.7%). Of these, 50 (92.6%) had an abnormal left ventricular ejection fraction (LVEF). At a median follow-up time after the CMR of 2.7 years, 105 survivors experienced the primary endpoint. On Kaplan–Meier analyses, the cumulative incidence of the primary endpoint was significantly higher in survivors with abnormal RVEF compared with those with normal RVEF (P = 0.002). However, on Cox multivariable analyses, RVEF was not associated with the primary endpoint (HR 1.04 per 5% decrease; 95% CI 0.93–1.17; P = 0.46) after adjustment for non-imaging variables and LVEF. RVEF was also not associated with the secondary endpoints. Among anthracycline-treated cancer survivors undergoing CMR for suspected cardiotoxicity, RV systolic dysfunction was present in one in five cases, accompanied by LV systolic dysfunction in nearly all cases, and was not independently associated with long-term outcomes.Keywords
Funding Information
- National Institutes of Health (K23HL132011, KL2TR000113-05, UL1TR002494)
This publication has 27 references indexed in Scilit:
- Assessment of right ventricular volumes and ejection fraction by echocardiography: from geometric approximations to realistic shapesEcho Research & Practice, 2015
- Normal values for cardiovascular magnetic resonance in adults and childrenJournal of Cardiovascular Magnetic Resonance, 2015
- Molecular Remodeling of Left and Right Ventricular Myocardium in Chronic Anthracycline Cardiotoxicity and Post-Treatment Follow UpPLOS ONE, 2014
- Left and right ventricular effects of anthracycline and trastuzumab chemotherapy: A prospective study using novel cardiac imaging and biochemical markersInternational Journal of Cardiology, 2013
- Cardiac Magnetic Resonance Imaging in the Evaluation of the Late Effects of Anthracyclines Among Long-Term Survivors of Childhood CancerJACC, 2013
- Standardized image interpretation and post processing in cardiovascular magnetic resonance: Society for Cardiovascular Magnetic Resonance (SCMR) Board of Trustees Task Force on Standardized Post ProcessingJournal of Cardiovascular Magnetic Resonance, 2013
- Reproducibility of Echocardiographic Techniques for Sequential Assessment of Left Ventricular Ejection Fraction and VolumesJACC, 2013
- Risk of Heart Failure in Breast Cancer Patients After Anthracycline and Trastuzumab Treatment: A Retrospective Cohort StudyJNCI: Journal of the National Cancer Institute, 2012
- Right Ventricular Plasticity and Functional ImagingPulmonary Circulation, 2012
- Cause of death in clinical researchJACC, 1999